Arlene Naranjo
About
Arlene Naranjo is a scholar working on Neurology, Molecular Biology and Cancer Research.
According to data from OpenAlex, Arlene Naranjo has authored 110 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Neurology, 44 papers in Molecular Biology and 38 papers in Cancer Research. Recurrent topics in Arlene Naranjo's work include Neuroblastoma Research and Treatments (93 papers), Cancer, Hypoxia, and Metabolism (38 papers) and Cancer therapeutics and mechanisms (29 papers). Arlene Naranjo is often cited by papers focused on Neuroblastoma Research and Treatments (93 papers), Cancer, Hypoxia, and Metabolism (38 papers) and Cancer therapeutics and mechanisms (29 papers). Arlene Naranjo collaborates with scholars based in United States, Canada and Switzerland. Arlene Naranjo's co-authors include Wendy B. London, Julie R. Park, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Michael D. Hogarty, Marguerite T. Parisi, Barry L. Shulkin, Katherine K. Matthay and Meredith S. Irwin and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Arlene Naranjo
101 papers receiving 3.4k citations
Hit Papers
Peers
Arlene Naranjo
Susan G. Kreissman United States
Allen Buxton United States
Howard M. Katzenstein United States
Thorsten Simon Germany
Adela Cañete Spain
Kim Kramer United States
Godelieve A.M. Tytgat Netherlands
Robert P. Castleberry United States
Victoria Castel Spain
Niels Carlsen Denmark
Citations per year, relative to Arlene Naranjo Arlene Naranjo (= 1×)
peers
Susan G. Kreissman
Countries citing papers authored by Arlene Naranjo
Since
Specialization
Citations
This map shows the geographic impact of Arlene Naranjo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arlene Naranjo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arlene Naranjo more than expected).
Fields of papers citing papers by Arlene Naranjo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Arlene Naranjo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arlene Naranjo. The network helps show where Arlene Naranjo may publish in the future.
Co-authorship network of co-authors of Arlene Naranjo
This figure shows the co-authorship network connecting the top 25 collaborators of Arlene Naranjo. A scholar is included among the top collaborators of Arlene Naranjo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arlene Naranjo. Arlene Naranjo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Berko, Esther R., Arlene Naranjo, Samantha N. McNulty, et al.. (2025). Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. Journal of Clinical Oncology. 43(14). 1673–1684.
2.
Sokol, Elizabeth, Navin Pinto, Susan G. Kreissman, et al.. (2024). Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group. SHILAP Revista de lepidopterología. 4. 100193–100193.
3.
Desai, Ami V., Arlene Naranjo, Kelly C. Goldsmith, et al.. (2024). A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.. Journal of Clinical Oncology. 42(16_suppl). 10004–10004.
4.
Katzenstein, Howard M., Arlene Naranjo, Sheena C. Tenney, et al.. (2024). Outcomes of patients with intermediate‐risk neuroblastoma presenting with motor deficits relating to intraspinal tumor extension: A report from the Children's Oncology Group study ANBL0531. Pediatric Blood & Cancer. 72(1). e31407–e31407.
5.
Brown, Erin G., E. Stanton Adkins, Peter Mattei, et al.. (2024). Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of Pediatric Surgery. 60(1). 161896–161896.
6.
Pinto, Navin, Arlene Naranjo, Xiangming Ding, et al.. (2023). Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Clinical Cancer Research. 29(8). 1546–1556.
7.
Bagatell, Rochelle, Steven G. DuBois, Arlene Naranjo, et al.. (2023). Children's Oncology Group's 2023 blueprint for research: Neuroblastoma. Pediatric Blood & Cancer. 70(S6). e30572–e30572.
8.
Campbell, Kevin, Pei‐Chi Kao, Arlene Naranjo, et al.. (2022). Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood & Cancer. 70(2). e30054–e30054.
9.
Asgharzadeh, Shahab, Araz Marachelian, Judith G. Villablanca, et al.. (2022). Expression of neuroblastoma‐related genes in bone marrow at end of high‐risk neuroblastoma therapy. Pediatric Blood & Cancer. 69(9). e29719–e29719.
10.
Vo, Kieuhoa T., Steven G. DuBois, John Neuhaus, et al.. (2022). Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood & Cancer. 69(9). e29616–e29616.
11.
Yu, Alice L., Andrew L. Gilman, M. Fevzi Özkaynak, et al.. (2021). Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research. 27(8). 2179–2189.
12.
Mayampurath, Anoop, Siddhi Ramesh, Meaghan Granger, et al.. (2021). Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clinical Cancer Informatics. 5(5). 1181–1188.
13.
Weiss, Brian, Gregory A. Yanik, Arlene Naranjo, et al.. (2021). A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study. Pediatric Blood & Cancer. 68(10). e29117–e29117.
14.
Lee, Sang Mee, Ami V. Desai, Samuel L. Volchenboum, et al.. (2021). Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Network Open. 4(7). e2116248–e2116248.
15.
Federico, Sara M., Wendy B. London, Arlene Naranjo, et al.. (2020). Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clinical Cancer Informatics. 4(4). 895–905.
16.
Özkaynak, M. Fevzi, Andrew L. Gilman, Wendy B. London, et al.. (2018). A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931. Frontiers in Immunology. 9. 1355–1355.
17.
Campbell, Kevin, Julie M. Gastier‐Foster, Arlene Naranjo, et al.. (2017). Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 123(21). 4224–4235.
18.
Ostler, Kelly R., Qiwei Yang, Timothy J. Looney, et al.. (2012). Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. Cancer Research. 72(18). 4714–4723.
19.
Naranjo, Arlene, Marguerite T. Parisi, Barry L. Shulkin, et al.. (2011). Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood & Cancer. 56(7). 1041–1045.
20.
London, Wendy B., Arlene Naranjo, Michael D. Hogarty, et al.. (2009). Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood & Cancer. 53(4). 563–569.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Susan G. Kreissman Breakdown of academic impact, for papers by Allen Buxton Breakdown of academic impact, for papers by Howard M. Katzenstein Breakdown of academic impact, for papers by Thorsten Simon Breakdown of academic impact, for papers by Adela Cañete Breakdown of academic impact, for papers by Kim Kramer Breakdown of academic impact, for papers by Godelieve A.M. Tytgat Breakdown of academic impact, for papers by Robert P. Castleberry Breakdown of academic impact, for papers by Victoria Castel Breakdown of academic impact, for papers by Niels Carlsen